Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 08:20PM GMT
Release Date Price: R$15.75
Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Okay. Great. I think we're going to get started. Thanks so much for joining us for the afternoon session. I'm Terence Flynn, the biopharma analyst here at Goldman Sachs. We're very pleased to have Eli Lilly with us this afternoon. Joining us from the company is Josh Smiley, CFO. Josh, thanks very much for taking the time.

Joshua L. Smiley
Eli Lilly and Company - Senior VP & CFO

Thanks for having us.

Questions & Answers

Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Maybe just to get started, big picture, given your background and experience, would just kind of love to hear your thoughts on this question about broader industry consolidation. There's been consolidation in the payer-provider side now over the last couple of years. We saw another large transaction earlier this year in the biopharma space. So do you think this is the start of a trend here in the biopharma space in response to kind of the payer-provider

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot